July 9, 2026 · Form 4 insider transaction
Schoenberg Mark sold 10,000 shares of UroGen Pharma Ltd. at $40.00 per share, a transaction worth $400.0K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.